{"DataElement":{"publicId":"7092878","version":"1","preferredName":"Anti-Thymocyte Globulin Source Type","preferredDefinition":"Information for the origin of immunosuppressive purified gamma globulin.","longName":"AGT_SCR","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7092877","version":"1","preferredName":"Anti-Thymocyte Globulin Source","preferredDefinition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease._Where something is available or from where it originates.","longName":"4182054v1.0:2223297v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"4182054","version":"1","preferredName":"Anti-Thymocyte Globulin","preferredDefinition":"A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","longName":"C278","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36A2E6C-D8A3-314A-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-27","modifiedBy":"ONEDATA","dateModified":"2014-02-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223297","version":"1","preferredName":"Source","preferredDefinition":"Where something is available.","longName":"C25683","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Source","conceptCode":"C25683","definition":"Where something is available or from where it originates.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B04C0-71B2-23A7-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D8E0CC-9958-2E5B-E053-F662850A802D","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"LEEW","dateModified":"2020-03-24","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7092874","version":"1","preferredName":"Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7092874v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Equine","valueDescription":"Equine","ValueMeaning":{"publicId":"7092875","version":"1","preferredName":"Equine","longName":"7092875v1.00","preferredDefinition":"The domestic horse, Equus caballus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Horse","conceptCode":"C14222","definition":"The domestic horse, Equus caballus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D6ADE6-0AF6-743B-E053-F662850A05E5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D6ADE6-0B0F-743B-E053-F662850A05E5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Rabbit","valueDescription":"Rabbit","ValueMeaning":{"publicId":"2578403","version":"1","preferredName":"Rabbit","longName":"2578403v1.00","preferredDefinition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rabbit","conceptCode":"C14264","definition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF50-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-24","endDate":null,"createdBy":"HARDINGR","dateCreated":"2006-03-24","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D6ADE6-0B19-743B-E053-F662850A05E5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D6ADE6-0AE1-743B-E053-F662850A05E5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":"AAML1831 - WL","administrativeNotes":"2023.8.8 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the source of anti-t","type":"Preferred Question Text","description":"What was the source of anti-thymocyte globulin ATG?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D6C2CD-92AC-10A6-E053-F662850A68FE","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"LEEW","dateModified":"2020-03-24","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}